Oliver Lenz
Janssen (Belgium)(BE)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, HIV/AIDS drug development and treatment, Systemic Lupus Erythematosus Research
Most-Cited Works
- → Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial(2014)434 cited
- → Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial(2014)373 cited
- → Hepatitis C virus drug resistance–associated substitutions: State of the art summary(2015)283 cited
- → Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study(2013)270 cited
- → Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial(2014)254 cited
- → Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial(2013)233 cited
- → Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor(2014)211 cited
- → In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435(2010)210 cited
- → In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor(2009)190 cited
- → Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study(2016)189 cited